A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) (BoB)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03767075|
Recruitment Status : Recruiting
First Posted : December 6, 2018
Last Update Posted : February 9, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
The Global objective of this Basket of Basket study is to evaluate the antitumor activity of each matched therapies that will be evaluated through the study in small molecularly selected populations.
The objective of module 1 will be to determine the overall response rate by RECIST 1.1 of atezolizumab in several arms. Subjects will be separated into arms depending on the mutations of their tumour. All patients in genomically selected populations will receive atezolizumab 1200 mg IV every 3 weeks
|Condition or disease||Intervention/treatment||Phase|
|Advanced Solid Tumor||Drug: Arm 1 - atezolizumab||Phase 2|
Basket studies are a new sort of clinical studies to identify patients with the same kind of mutations and treat them with the same drug, irrespective of their specific cancer type. In basket studies, depending on the mutation types, patients are classified into "baskets". Targeted therapies that block that mutation are then identified and assigned to baskets where patients are treated accordingly.
This protocol has two parts: part A (iPROFILER), which includes the common procedures for tumor molecular profiling and treatment recommendation, and part B (iBASKET), which corresponds to the therapeutic portion The purpose of part A (iPROFILER) of this study is to test participants' tumour tissue in order to identify whether their tumour has certain mutations in cancer-related genes. It is known that gene mutations of tumours contribute to their origin and growth and determine whether the tumour will respond to particular cancer drugs. This test will provide information about potential targeted therapies that specifically attack those gene mutations. The purpose of part B (iBASKET) of this study is to offer participants a personalised anti-cancer treatment based on the gene mutations that are found in their tumour. Participants taking part in this module 1 of part B (iBASKET), in genomically selected populations, will receive atezolizumab 1200mg intravenously every 3 weeks, following the analysis of their tumour in part A (iPROFILER). Participants will be able to take atezolizumab for as long as their tumour doesn't grow and for as long as they don't have any side-effects which prevent them from continuing treatment.
The study will have a 2-year recruitment period. The aim of the study is to determine which genomically selected populations respond effectively to the targeted treatment, atezolizumab. Approximately 1000 participants will be enrolled into part A (iPROFILER), with approximately 100 participants being recruited into module 1 of part B (iBASKET)."
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1000 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||
|Masking:||None (Open Label)|
|Masking Description:||no masking is used. All involved know the identity of the intervention assignment|
|Official Title:||Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumours|
|Actual Study Start Date :||December 10, 2018|
|Estimated Primary Completion Date :||May 2025|
|Estimated Study Completion Date :||November 2026|
Experimental: Module 1 Arm 1 - atezolizumab
Genomically selected populations will all receive the same drug (6 groups of mutation will be evaluated)
Subjects will be recruited and allocated to arms according to their biomarker profile. It is assumed that 1000 subjects will need to be screened in part A in order to enroll 100 patients in part B of module 1.
Drug: Arm 1 - atezolizumab
Module 1 - 1200mg, IV, every 3 weeks, until progression or unacceptable toxicity develops.
- Overall response rate by RECIST 1.1 [ Time Frame: 12 weeks ]For the purposes of the primary endpoint of this study, subjects will be evaluated for response and progression using the new international criteria proposed by the revised RECIST guideline (version 1.1). Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). The patient's best response assignment will depend on the achievement of both measurement and confirmation criteria.
- Mean progression free survival (PFS by RECIST 1.1) of the subjects participating in iBASKET [ Time Frame: through study completion, an average of 3 years. ]
- Progression Free Survival (PFS by RECIST 1.1) [ Time Frame: 6 months. ]
- Mean overall survival of subjects treated with targeted therapy in iBASKET [ Time Frame: through study completion, an average of 3 years. ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Histologically or cytologically confirmed malignancy that is metastatic or unresectable,
- who have progressed to standard therapy,
- who are receiving a standard anticancer treatment but no subsequent approved treatment would be available upon progression,
- who are unable to receive standard therapy, or
- for whom standard therapy does not exist
- ECOG performance status of 0 or 1.
- 18 year-old or older.
- Measurable disease according to RECIST 1.1.
- Enough tumor tissue for molecular analysis
- Patients providing formalin-fixed paraffin embedded tissue (FFPE) must provide a minimum amount of tissue ranging from 20 to 28 slides depending on the sample tumor cellularity. If there is not enough archival tissue to meet this criterion, the patient must undergo a tumor biopsy.
- Patients providing fresh frozen tissue must provide 4 core biopsies or equivalent. Fresh frozen tissue must be preferentially collected from a tumor biopsy; hence, patients must have disease amenable to be biopsied. Otherwise, the patient should have fresh frozen tumor tissue stored in a biobank or biorepository.
Efforts will be made to provide fresh frozen tissue in at least one quarter of the participating patients.
- The proportion of patients that might provide fresh frozen tissue might change based on the results from the molecular analysis.
- Since some of the tests are performed in FFPE tissue, patients providing fresh frozen tissue from a recent biopsy will have part of the sample processed in formalin-fixed paraffin embedded tissue (FFPE) as per Laboratory manual.
- Adequate hematological, renal and hepatic function:
For patients requiring a tumor biopsy, patients must have adequate coagulation function
- Quick time ≥ 60%
- Ability to understand and the willingness to sign a written informed consent document.
- Known brain metastases or leptomeningeal disease
- Spinal cord compression not definitively treated with surgery and/or radiation.
- Uncontrolled intercurrent illness including, but not limited to, active infection, symptomatic congestive heart failure, LVEF < 50%, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Inability to swallow tablets or capsules
- Known HIV, hepatitis B or hepatitis C infection.
- Known history of malabsorption.
- Pregnant and lactating women
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03767075
|Contact: Xenia Villalobos Alberú, PhD||+34 932 543 450 ext firstname.lastname@example.org|
|Contact: Susana Muñoz||+34 934 893 000 ext email@example.com|
|Institut Gustave Roussy||Recruiting|
|Villejuif, France, 94800|
|Contact: Christophe Massard|
|Deutsches Krebsforschungszentrum (NCT/DKFZ)||Recruiting|
|Heidelberg, Baden-Wurtemberg, Germany, 69120|
|Contact: Richard Schlenk, MD|
|Nederland Kanker Instituut (NKI)||Recruiting|
|Amsterdam, Netherlands, 1066|
|Contact: Frans Opdam, MD|
|Hospital Vall d'Hebron||Recruiting|
|Barcelona, Spain, 08035|
|Contact: Irene Braña, MD|
|Karolinska University Hospital Solna||Recruiting|
|Stockholm, Sweden, 17176|
|Contact: Luigi de Petris, MD|
|Cancer Research UK Cambridge Centre||Recruiting|
|Cambridge, United Kingdom, CB2 0QQ|
|Contact: Richard Baird, MD|
|Study Chair:||Jordi Rodon, MD||MD Anderson|
|Responsible Party:||Vall d'Hebron Institute of Oncology|
|Other Study ID Numbers:||
2017-005108-89 ( EudraCT Number )
MO39164 ( Other Identifier: Roche Internal Identifier )
|First Posted:||December 6, 2018 Key Record Dates|
|Last Update Posted:||February 9, 2023|
|Last Verified:||February 2023|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||No|
Advanced Solid Tumor
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological